Standard BioTools
LAB

Standard BioTools (LAB) stock price, chart and financials

Price chart

−54.19% over 1Y
Oct 15, 2025Low $0.63 · High $1.68Oct 15, 2026

Financials

Net margin
100.37%

Company profile

Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.

Frequently asked questions

  • Is Standard BioTools (LAB) profitable?

    Yes. Standard BioTools earned $84.9M in net income over the trailing twelve months, a net margin of 100.37%.

  • How much revenue does Standard BioTools (LAB) make?

    Standard BioTools generated $84.6M in revenue over the trailing twelve months, down 7.62% year over year.

  • What is LAB's P/E ratio?

    Standard BioTools trades at 3.0 times trailing twelve-month earnings, on an EPS of $0.22.

  • How do I buy stock in Standard BioTools (LAB)?

    LAB trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.

Quotes and charts are not real-time and must not be relied on for trade decisions or valuation.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.